Analyst Price Target is $11.00
▲ +340.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Evaxion Biotech A/S in the last 3 months. The average price target is $11.00, with a high forecast of $14.00 and a low forecast of $8.00. The average price target represents a 340.00% upside from the last price of $2.50.
Current Consensus is
Buy
The current consensus among 2 investment analysts is to buy stock in Evaxion Biotech A/S. This rating has held steady since March 2024, when it changed from a Moderate Buy consensus rating.
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Read More